valacyclovir and Fever

valacyclovir has been researched along with Fever* in 8 studies

Reviews

1 review(s) available for valacyclovir and Fever

ArticleYear
80-year-old man with fever and ear pain.
    Mayo Clinic proceedings, 2004, Volume: 79, Issue:8

    Topics: Acetates; Acyclovir; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Earache; Fever; Gabapentin; gamma-Aminobutyric Acid; Herpes Zoster; Humans; Male; Oxycodone; Pain; Patient Selection; Polymerase Chain Reaction; Risk Factors; Valacyclovir; Valine

2004

Trials

1 trial(s) available for valacyclovir and Fever

ArticleYear
Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses.
    American journal of veterinary research, 2017, Volume: 78, Issue:10

    OBJECTIVE To determine whether prophylactic administration of valacyclovir hydrochloride versus initiation of treatment at the onset of fever would differentially protect horses from viral replication and clinical disease attributable to equine herpesvirus type-1 (EHV-1) infection. ANIMALS 18 aged mares. PROCEDURES Horses were randomly assigned to receive an oral placebo (control), treatment at detection of fever, or prophylactic treatment (initiated 1 day prior to viral challenge) and then inoculated intranasally with a neuropathogenic strain of EHV-1. Placebo or valacyclovir was administered orally for 7 or 14 days after EHV-1 inoculation or detection of fever (3 horses/group). Effects of treatment on viral replication and clinical disease were evaluated. Plasma acyclovir concentrations and viremia were assessed to determine inhibitory concentrations of valacyclovir. RESULTS Valacyclovir administration decreased shedding of virus and viremia, compared with findings for control horses. Rectal temperatures and clinical disease scores in horses that received valacyclovir prophylactically for 2 weeks were lower than those in control horses. The severity of but not the risk for ataxia was decreased by valacyclovir administration. Viremia was decreased when steady-state trough plasma acyclovir concentrations were > 0.8 μg/mL, supporting the time-dependent activity of acyclovir. CONCLUSIONS AND CLINICAL RELEVANCE Valacyclovir treatment significantly decreased viral replication and signs of disease in EHV-1-infected horses; effects were greatest when treatment was initiated before viral inoculation, but treatment was also effective when initiated as late as 2 days after inoculation. During an outbreak of equine herpesvirus myeloencephalopathy, antiviral treatment may be initiated in horses at various stages of infection, including horses that have not yet developed signs of viral disease.

    Topics: Acyclovir; Animals; Antiviral Agents; Female; Fever; Herpesviridae Infections; Herpesvirus 1, Equid; Horse Diseases; Horses; Premedication; Valacyclovir; Valine; Viremia; Virus Replication

2017

Other Studies

6 other study(ies) available for valacyclovir and Fever

ArticleYear
Emphysematous cystitis associated with voiding dysfunction from herpes zoster.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019, 06-03, Volume: 191, Issue:22

    Topics: Aged, 80 and over; Antiviral Agents; Cystitis; Emphysema; Female; Fever; Herpes Zoster; Humans; Peripheral Nervous System Diseases; Treatment Outcome; Urinary Bladder, Underactive; Urinary Tract Infections; Valacyclovir

2019
Transmission of chromosomally integrated human herpesvirus 6 via cord blood transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:1

    Chromosomally integrated human herpesvirus 6 (ciHHV-6) can be transmitted via allogeneic hematopoietic cell transplantation. To date, only a few cases have been reported. Here, we report a case identified as transmission of ciHHV-6 via cord blood transplantation. Distinguishing transmission of ciHHV-6 from HHV-6 reactivation in cases with high titer of HHV-6 DNA load after transplantation is important to prevent unnecessary exposure to antiviral drugs that could be toxic.

    Topics: Acyclovir; Antibiotic Prophylaxis; Antiviral Agents; Busulfan; Child, Preschool; Chromosomes, Human, Pair 22; Cord Blood Stem Cell Transplantation; DNA, Viral; Exanthema; Fetal Blood; Fever; Herpesvirus 6, Human; Humans; Immunocompromised Host; Male; Melphalan; Myeloablative Agonists; Roseolovirus Infections; Transplantation Conditioning; Unrelated Donors; Valacyclovir; Valine; Viral Load; Virus Integration

2017
[Varicella-zoster virus infection of the central nervous system].
    Medicina clinica, 2014, Jul-07, Volume: 143, Issue:1

    Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Encephalitis, Varicella Zoster; Female; Fever; Herpes Zoster; Humans; Male; Middle Aged; Spain; Valacyclovir; Valine; Young Adult

2014
Fever and acute cytomegalovirus hepatitis in Crohn's disease.
    Revista espanola de enfermedades digestivas, 2014, Volume: 106, Issue:3

    Topics: Acyclovir; Adult; Antiviral Agents; Crohn Disease; Cytomegalovirus Infections; Fever; Humans; Ilium; Male; Valacyclovir; Valine

2014
Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies.
    Veterinary microbiology, 2009, Mar-30, Volume: 135, Issue:3-4

    The purpose of the current study was to investigate the therapeutic efficacy of valacyclovir against EHV1 in a controlled study. Eight naïve Shetland ponies were inoculated with 10(6.5) TCID(50) of the neuropathogenic strain 03P37. Four ponies were treated with valacyclovir at a dosage of 40mg/kg bodyweight, 3 times daily, for 5 (n=2) or 7 (n=2) consecutive days, while the other four ponies served as untreated controls. The treatment regimen started 1h before inoculation. Ponies were monitored daily for clinical signs. At 0, 1, 2, 3, 4, 5, 7, 9, 11, 14, 17 and 21 days post inoculation (d pi), a nasopharyngeal mucus sample was taken to determine viral shedding. At the same time points, blood was collected and peripheral blood mononuclear cells (PBMC) were isolated to determine viremia. During the treatment, blood samples were collected 6 times daily, i.e. just before valacyclovir administration and 1h later, to determine the concentration of acyclovir in plasma. Also a nasopharyngeal swab was taken to measure the acyclovir concentration in nasal secretion. No differences could be noticed between valacyclovir-treated and untreated ponies. The clinical signs, the viral shedding and the viremia were similar in both the groups. Plasma acyclovir concentration could be maintained above the EC(50)-value of EHV1 during 50% of the entire treatment period in valacyclovir-treated ponies. Acyclovir could be detected in nasal swabs at concentrations varying from 50% to 100% of the corresponding plasma concentration. Although sufficiently high acyclovir levels could be reached in plasma and nasal mucus, no effect was seen of the treatment with valacyclovir on clinical signs, viral shedding and viremia of EHV1-infected ponies.

    Topics: Acyclovir; Animals; Antiviral Agents; Body Temperature; Dose-Response Relationship, Drug; Fever; Herpesviridae Infections; Herpesvirus 1, Equid; Horse Diseases; Horses; Valacyclovir; Valine; Virus Shedding

2009
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Haematologica, 2005, Volume: 90, Issue:12

    Despite increasing intensity and profound immunosuppression associated with newer therapies for hematologic malignancies, little information exists regarding cytomegalovirus (CMV) reactivation in settings other than allogeneic stem cell transplantation (SCT).. We reviewed the epidemiology of CMV disease in patients who were CMV polymerase chain reaction (PCR) positive during treatment for hematologic malignancies without allogeneic SCT from June 1999 to June 2004.. Thirty-six patients with CMV reactivation were identified. Of these, 92% were undergoing investigation for fever. Fifteen patients with CMV DNAemia were treated with ganciclovir without CMV disease developing. Notably, 20 patients with untreated CMV DNAemia did not develop CMV disease during a median follow-up of 3.5 (1-19) months. The highest rates of reactivation were observed with HyperCVAD (7.8%) and alemtuzumab (50%).. We recommend that screening for CMV DNAemia be instituted and pre-emptive therapy contemplated for asymptomatic CMV reactivation only in patients receiving alemtuzumab therapy, but not routinely for other patients outside the allogeneic SCT setting. Indeed for such patients, detection of isolated CMV DNAemia does not imply the need for immediate therapy and future studies are needed to validate PCR detection of CMV DNA and CMV DNA titers as predictors for CMV disease.

    Topics: Acyclovir; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Diphtheria Toxin; DNA, Viral; Doxorubicin; Female; Fever; Follow-Up Studies; Ganciclovir; Hematologic Neoplasms; Humans; Interleukin-2; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Transplantation, Autologous; Valacyclovir; Valine; Vidarabine; Vincristine; Viremia; Virus Activation

2005
chemdatabank.com